US
Updated
Reviewed by Chandani Patel
US Antimicrobial Resistance Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $1.46 Bn.
Canada at 6.9% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$764.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $1.39 Bn | — | — |
| 2025 (base) | $1.46 Bn | +$66.7 Mn | — |
| 2026 (forecast) | $1.53 Bn | +$69.9 Mn | +4.8% |
| 2027 (forecast) | $1.60 Bn | +$73.2 Mn | +9.8% |
| 2028 (forecast) | $1.68 Bn | +$76.8 Mn | +15.1% |
| 2029 (forecast) | $1.76 Bn | +$80.4 Mn | +20.6% |
| 2030 (forecast) | $1.84 Bn | +$84.3 Mn | +26.4% |
| 2031 (forecast) | $1.93 Bn | +$88.4 Mn | +32.5% |
| 2032 (forecast) | $2.02 Bn | +$92.6 Mn | +38.8% |
| 2033 (forecast) | $2.12 Bn | +$97.0 Mn | +45.5% |
| 2034 (forecast) | $2.22 Bn | +$101.7 Mn | +52.5% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$1.46 Bn
China
$322.7 Mn
Canada
$313.2 Mn
Japan
$216.0 Mn
Germany
$140.5 Mn
Brazil
$99.9 Mn
UK
$86.2 Mn
France
$87.1 Mn
Italy
$74.8 Mn
Spain
$64.6 Mn
Saudi Arabia
$63.7 Mn
Ecuador
$61.1 Mn
India
$60.5 Mn
Mexico
$48.2 Mn
Australia
$48.6 Mn
Russia
$38.1 Mn
New Zealand
$29.1 Mn
South Africa
$25.9 Mn
UAE
$19.4 Mn
Philippines
$8.5 Mn
Egypt
$8.5 Mn
Malaysia
$6.0 Mn
Hong Kong
$5.2 Mn
Singapore
$4.4 Mn
Thailand
$4.2 Mn
Kenya
$2.7 Mn
| Market size, 2025 | $1.46 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $2.22 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 4.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Technology, setting and end user (see all) |
| Key players | bioMérieux SA, BD (Becton, Dickinson), Beckman Coulter (Danaher), Accelerate Diagnostics, Inc., Thermo Fisher Scientific Inc. (see all) |
| Regulator in the US | FDASource: US Food and Drug Administration. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Antimicrobial resistance diagnostics show which antibiotics will work against an infection, helping doctors avoid ineffective drugs.
Key segments of the antimicrobial Resistance Diagnostics market include technology (Automated AST Systems, Molecular Resistance Tests and Rapid Phenotypic AST) and setting (Hospital Labs and Reference Labs).
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the antimicrobial Resistance Diagnostics market.
New vaccines, rapid tests and public-private funding for neglected diseases give the antimicrobial Resistance Diagnostics market room to grow, especially in Asia, Africa and Latin America.
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the antimicrobial Resistance Diagnostics market.
The antimicrobial Resistance Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
BD (Becton, Dickinson)Accelerate DiagnosticsThe FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2]
[1] US Food and Drug Administration. Checked 14 Nov 2026.
[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how antimicrobial Resistance Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.
What doctors and scientists are doing in Antimicrobial Resistance Diagnostics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
From our blog
Digital Health · US
Healthcare Services · US
Pharmaceuticals · US
OTC & Nutraceuticals · US
Pharmaceuticals · US
OTC & Nutraceuticals · US